AFRESA(R) Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function In Patients Over Four Years Of Treatment

AFRESA(R) Phase 3 Data Show Sustained Glycemic Control, Normal Lung Function In Patients Over Four Years Of Treatment
AFRESA® (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, showed no significant changes in pulmonary function and sustained glycemic control in adult patients with type 2 diabetes over four years of continuous treatment, according to data presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes.